Alexion Pharmaceuticals (ALXN) fired its CEO and chief financial, as it is in the midst of an internal investigation looking into allegations of improper sales practices connected with its top selling drug Soliris. Soliris sales have totaled $2.2 billion in the first three quarters of the year. Alexion also said its 10-Q filling for the third quarter will now be filed in January. An Alexian Board member, David Brennan, is taking over immediately as interim CEO. He is a former CEO at AstraZeneca (AZN) .
More from Video
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money Video Wrap: Citi Surges as View of Stability Saves Sentiment
Citi overcame a mixed print to send its stock surging on Monday.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.